Third Harmonic Bio, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Third Harmonic Bio, Inc. has dissolved, leading to the cancellation of shares and derivative securities, with a liquidation distribution of $5.35 per share.
An insider at Third Harmonic Bio, Inc. reported the cancellation of stock options due to the company's dissolution and a liquidation distribution.
Third Harmonic Bio's Chief Financial Officer, Christopher M. Murphy, reported the cancellation of 47,500 restricted stock units and common shares due to the company's dissolution, receiving a $5.35 per share liquidation distribution.
Third Harmonic Bio, Inc. Director Mark T. Iwicki reports the cancellation of shares and stock options due to the company's dissolution, receiving a $5.35 per share liquidation distribution.
A director at Third Harmonic Bio, Inc. reported the cancellation of 120,166 stock options in connection with the company's dissolution, with a liquidation distribution of $5.35 per share.
A director of Third Harmonic Bio, Inc. reported the cancellation of over 5.7 million shares and stock options in connection with the company's dissolution and a $5.35 per share liquidation distribution.
Form 4: Third Harmonic Bio CFO Christopher Murphy Reports Acquisition of 30,000 Restricted Stock Units
Christopher Murphy, CFO of Third Harmonic Bio, reports the acquisition of 30,000 restricted stock units (RSUs) on March 1, 2025, according to a Form 4 filing with the SEC.
Third Harmonic Bio's Chief Financial Officer, Christopher M. Murphy, was granted stock options and restricted stock units as part of the company's annual equity refresh program.
Third Harmonic Bio's Chief Operating Officer, Jennifer Dittman, was granted stock options and restricted stock units as part of the company's annual equity refresh.
Third Harmonic Bio's Chief Medical Officer, Edward R. Conner, was granted stock options and restricted stock units as part of the company's annual refresh equity grant process.
Julie Person, Chief Administrative Officer of Third Harmonic Bio, was granted stock options and restricted stock units as part of the company's annual equity refresh.
Form 4: Third Harmonic Bio Chief Scientific Officer Receives Stock Options and Restricted Stock Units
Third Harmonic Bio's Chief Scientific Officer, Christopher Dinsmore, was granted stock options and restricted stock units as part of the company's annual equity refresh.
Third Harmonic Bio's Chief Nonclinical Development Officer, Dennis Dean, was granted stock options and restricted stock units as part of the company's annual refresh equity grant process.
Third Harmonic Bio's CEO, Natalie Holles, received stock options for 400,000 shares and 50,000 restricted stock units as part of the company's annual equity refresh.
Third Harmonic Bio's Chief Medical Officer, Edward R. Conner, exercised stock options and sold the resulting shares on November 8, 2024, according to a recent SEC filing.
Atlas Venture Fund XI distributed 515,688 shares of Third Harmonic Bio to its partners on November 1, 2024, as part of a pre-arranged plan.
BVF Partners L.P. and affiliated entities report a decrease in their holdings of Third Harmonic Bio, Inc. common stock, resulting in them no longer beneficially owning 10% or more of the outstanding shares.
Edward R. Conner, Chief Medical Officer of Third Harmonic Bio, exercised stock options and sold shares on October 28, 2024, according to a Form 4 filing.
Third Harmonic Bio's Chief Medical Officer, Edward R. Conner, exercised stock options and sold shares on September 19, 2024, according to a Form 4 filing.
Julie Person, Chief Administrative Officer of Third Harmonic Bio, reports the exercise of stock options and subsequent sale of shares on September 18 and 19, 2024, according to a Form 4 filing.
Christopher Dinsmore, Chief Scientific Officer of Third Harmonic Bio, received 297,000 employee stock options on May 16, 2024, according to an amended SEC Form 4 filing.
Form 4: Third Harmonic Bio Executive Julie Person Executes Stock Option and Sells Shares Under 10b5-1 Plan
Julie Person, Chief Administrative Officer of Third Harmonic Bio, exercised stock options and sold 10,000 shares of common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Jennifer Dittman, Chief Development Operations Officer at Third Harmonic Bio, reports the acquisition and disposal of company stock and stock options.
Mark T Iwicki, a director of Third Harmonic Bio, Inc., acquired 20,000 stock options on June 6, 2024.
Director Hans Martin Seidel acquired 20,000 stock options in Third Harmonic Bio, Inc. on June 6, 2024.
Director Thomas P. Soloway acquired 20,000 stock options in Third Harmonic Bio, Inc. on June 6, 2024.
Michael Gladstone, a director at Third Harmonic Bio, acquired stock options for 20,000 shares on June 6, 2024.
Director David P. Bonita acquired 20,000 stock options in Third Harmonic Bio, Inc. on June 6, 2024.
Jennifer Dittman, Chief Development Operations Officer of Third Harmonic Bio, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Christopher Dinsmore, Chief Scientific Officer of Third Harmonic Bio, Inc., was granted stock options for 210,000 shares on May 16, 2024.